CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology
- Inobrodib is a pioneering drug targeting twin tumour drivers p300/CBP, providing a new way to treat specific cancers
- Objective responses have been observed in multiple settings, including as monotherapy in relapsed refractory multiple myeloma
- ASH is the annual flagship scientific and clinical haematology meeting which is taking place in New Orleans on 9-13 December 2022
Cambridge, UK, November 4th, 2022 – CellCentric, a privately owned, clinical stage biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces that the Chief Investigator of its haematological malignancies programme, Professor Tim Somervaille, will be presenting compelling pre-clinical and early phase clinical activity data for inobrodib (CCS1477) at the American Society of Haematology (ASH) Annual Meeting and Exposition 2022, in New Orleans on the 9-13th December.
